Skrifvars MB, et al. - Researchers focused on acute kidney injury (AKI) as well as its prevention using erythropoietin (EPO) in this pre-planned analysis of patients with traumatic brain injury (TBI) who were randomized to weekly EPO (40 000 units) or placebo (0.9% sodium chloride) subcutaneously up to three doses or until intensive care unit (ICU) discharge in the EPO-TBI trial. Using the Kidney Disease Improving Global Outcome (KDIGO) classification, categorization of creatinine levels and urinary output (up to 7 days) was done. A more common development of AKI was observed in male patients and those with severe vs moderate TBI. AKI appeared to be related to worse outcome. Predictors of time to AKI were male gender and severity of TBI. Time to mortality was predicted by KDIGO stage 1, KDIGO stage 2 and KDIGO stage 3. EPO did not prevent AKI after TBI.